10-Q: SAB Biotherapeutics Secures $175M Funding

SAB Biotherapeutics reported increased net losses and no revenue for Q2 2025, but secured $175 million in gross proceeds from a Series B private placement to fund its lead T1D candidate's Phase 2b study.

Summary

• SAB Biotherapeutics, a clinical-stage biopharmaceutical company, reported a net loss of $10.1 million for the three months ended June 30, 2025, an increase from $7.3 million in the same period last year.
• For the six months ended June 30, 2025, the net loss was $15.3 million, up from $12.4 million in the prior year period.
• The company recognized no revenue for both the three and six months ended June 30, 2025, a 100% decrease from $0.3 million and $1.2 million, respectively, in the corresponding 2024 periods, due to the termination of a government contract.
• Research and development expenses increased by 2.6% to $7.0 million for the three months ended June 30, 2025, driven by higher salaries and benefits ($0.8 million increase) and clinical trial costs ($1.2 million increase).
• General and administrative expenses decreased by 24.9% to $2.7 million for the three months ended June 30, 2025.
• As of June 30, 2025, cash and cash equivalents stood at $3.7 million, down from $8.9 million at December 31, 2024.
• The accumulated deficit reached $139.5 million as of June 30, 2025.
• Subsequent to the reporting period, on July 21, 2025, the company secured approximately $175 million in gross proceeds from a Series B private placement offering.
• These proceeds are intended to fund the Phase 2b SAFEGUARD study of SAB-142, its lead candidate for Type 1 Diabetes (T1D), and for general corporate purposes.
• The Series B Preferred Stock issued in the private placement is convertible into 100,000,000 shares of common stock, subject to stockholder approval, representing 2,690% of total common stock outstanding as of June 30, 2025.

Sentiment

Score: 6

Explanation: The sentiment is cautiously positive. While the company reported significant losses and no revenue, the subsequent $175 million capital raise is a critical lifeline that funds the pivotal Phase 2b study for its lead candidate, SAB-142. This funding addresses immediate liquidity concerns and demonstrates investor confidence in the company's platform and clinical program. However, the substantial dilution potential from the Series B offering and the inherent high risks of clinical-stage biopharmaceutical development temper the overall positive outlook.

Positives

• Successfully secured approximately $175 million in gross proceeds from a Series B private placement, significantly improving liquidity and funding for key clinical trials.
• Existing resources, bolstered by the recent capital raise, are projected to cover operating cash needs for the next twelve months.
• Received Investigational New Drug (IND) clearance from the FDA in May 2024 for SAB-142.
• Announced positive topline data from the Phase 1 clinical trial of SAB-142 in January 2025.
• Held a constructive Type B meeting with the FDA on May 29, 2025, achieving alignment on the design and advancement of the Phase 2b SAFEGUARD study for SAB-142.
• Net cash used in operating activities decreased by $3.5 million for the six months ended June 30, 2025, compared to the same period in 2024, indicating improved operational cash burn.
• Net cash provided by investing activities significantly improved, shifting from a $20.1 million use in H1 2024 to a $9.9 million provision in H1 2025, primarily due to decreased purchases and increased sales/maturities of short-term investments.
• General and administrative expenses decreased by 24.9% for the three months ended June 30, 2025, and 27.2% for the six months ended June 30, 2025, reflecting cost management efforts.

Negatives

• Reported increased net losses, with a net loss of $10.1 million for Q2 2025 (vs. $7.3 million in Q2 2024) and $15.3 million for H1 2025 (vs. $12.4 million in H1 2024).
• Experienced a 100% decrease in revenue for both the three and six months ended June 30, 2025, due to the termination of the JPEO Rapid Response Contract.
• Cash and cash equivalents significantly declined to $3.7 million as of June 30, 2025, from $8.9 million at December 31, 2024, prior to the subsequent capital raise.
• Total current assets decreased substantially to $9.3 million as of June 30, 2025, from $23.8 million at December 31, 2024.
• Accumulated deficit increased to $139.5 million as of June 30, 2025, indicating continued historical losses.
• Interest income decreased significantly by 96.4% for Q2 2025 and 91.3% for H1 2025, primarily due to lower interest-earning cash and investment balances.
• The company anticipates continued and increasing losses for the foreseeable future as it develops product candidates and seeks regulatory approvals.

Risks

• The company will require additional capital to fund operations beyond the next twelve months and may not be able to raise such financing on acceptable terms or at all.
• Inability to raise additional capital could force the company to scale back or discontinue product candidate advancement, reduce headcount, liquidate assets, file for bankruptcy, reorganize, merge with another entity, or cease operations.
• The obligation to file a registration statement for the resale of common stock underlying the Series B Preferred Stock and warrants could lead to a significant decline in the market price of common stock due to potential dilution (100,000,000 common shares from Series B Preferred, representing 2,690% of total common stock outstanding as of June 30, 2025).
• The perception that holders of a large number of securities intend to sell them could also reduce the market price of common stock and public warrants.
• The company currently has no commercially approved products, and there is no assurance that research and development will be successfully commercialized.
• Developing and commercializing a product requires significant time and capital and is subject to regulatory review, approval, and competition.
• The company operates in an environment of rapid change and is dependent upon the continued services of its employees and obtaining and protecting intellectual property.
• There is an estimated 38.5% probability of dissolution should the company's intellectual property fail to yield positive results in forthcoming clinical trials, potentially leading to dissolution before 2028.

Future Outlook

The company anticipates continued net losses for the foreseeable future, expecting them to increase as it advances product candidates, seeks regulatory approvals, and begins commercialization. Research and development expenses are expected to increase as the lead therapeutic candidate progresses through Phase 2 clinical trials and as the company invests in the necessary foundation for potential commercialization. General and administrative expenses are also expected to rise with workforce expansion and increased operational complexity. Future interest income will largely depend on total liquid cash and investment balances, influenced by capital resources and future fundraising activities. The company intends to utilize data from the Phase 2b SAFEGUARD study as supportive evidence for future regulatory approval of SAB-142.

Management Comments

• "Based on our current level of operating expenses, existing resources will be sufficient to cover operating cash needs through the twelve months following the date of this report." (referring to post-Series B Offering funds)
• "In the future, we may seek additional funding through a combination of equity or debt financings, or other third-party financing, collaborative or other funding arrangements."
• "If we are unable to raise additional capital when required or on acceptable terms, we may be required to scale back or discontinue the advancement of product candidates, reduce headcount, liquidate assets, file for bankruptcy, reorganize, merge with another entity, or cease operations."
• "We expect Research and Development expenses to increase in future years as we advance our lead therapeutic candidate through Phase 2 clinical trials and invest in the necessary foundation to support potential commercialization."
• "We anticipate that general and administrative expenses will rise as we expand our workforce and invest in the advancement of our lead therapeutic candidate in preparation for potential commercialization."
• "The FDA provided clear, constructive, and actionable guidance during the discussion leading to alignment on the design and advancement of our Phase 2b SAFEGUARD study."
• "SAB confirmed its intent with the FDA to utilize the data from this study as supportive evidence for future regulatory approval."

Industry Context

SAB Biotherapeutics operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically targeting autoimmune disorders with its unique human polyclonal immunotherapeutic antibodies. The focus on Type 1 Diabetes (T1D) with SAB-142 positions it in a market with significant unmet medical needs. The company's proprietary platform, which produces disease-targeted hIgG without human plasma donors and has no biosimilar pathway, offers a differentiated approach. The successful IND clearance and positive Phase 1 data for SAB-142 are critical milestones in a sector where clinical trial success is paramount for valuation and future growth. The substantial capital raise, while dilutive, is a common and necessary step for clinical-stage biotech companies to fund expensive late-stage trials and advance towards potential commercialization, reflecting investor confidence in the platform and lead candidate despite the inherent risks.

Comparison to Industry Standards

• The company's approach of developing human polyclonal immunotherapeutic antibodies (hIgG) without human donors or convalescent plasma is a differentiated strategy compared to many competitors focusing on monoclonal antibodies or traditional plasma-derived products. This unique platform, utilizing transchromosomic cattle (Tc Bovine), aims to provide a significant barrier to competitive polyclonal approaches due to its non-biosimilar pathway.
• The lead candidate, SAB-142, is a human anti-thymocyte globulin (ATG) for Type 1 Diabetes (T1D). While rabbit ATG (rATG) has shown clinical validation in T1D, SAB-142 aims for superior efficacy and safety, particularly targeting zero-serum sickness rate and zero incidence of neutralizing anti-drug antibodies (ADA), which are known issues with some existing antibody therapies.
• The company's financial position, characterized by significant net losses and an accumulated deficit of $139.5 million, is typical for a clinical-stage biopharmaceutical company that has not yet commercialized a product. Companies like Moderna (pre-COVID vaccine) or smaller biotechs often operate at a loss for years, relying on capital raises to fund extensive R&D and clinical trials.
• The recent $175 million capital raise is a substantial amount for a company of this size, indicating significant investor confidence in its technology and pipeline, especially for a Phase 2b study. This is comparable to funding rounds seen in other promising biotech firms advancing into mid-stage clinical development, such as those seen with companies like Vertex Pharmaceuticals in their early stages of developing therapies for cystic fibrosis, or smaller firms like Provention Bio (now part of Sanofi) which also focused on T1D prevention and required significant capital for clinical trials.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material litigation.
• No pending or threatened litigation against the company is expected to have a material adverse effect on its financial condition, results of operations, or liquidity.

Related Party Transactions

• No related party transactions with beneficial owners of 5% or more of any class of voting securities, immediate family members, or entities in which any of the foregoing is an executive officer or 5% owner, for the three and six months ended June 30, 2025 and 2024.

Stakeholder Impact

• **Shareholders:** Significant potential dilution from the Series B Offering (100,000,000 common shares convertible from preferred stock, representing 2,690% of current outstanding shares) could negatively impact existing share price and ownership percentage. However, the capital raise provides crucial funding for clinical development, which could lead to long-term value if SAB-142 is successful.
• **Employees:** The capital raise secures funding for continued operations and advancement of the lead candidate, potentially ensuring job security and continued investment in R&D personnel. Management anticipates expanding the workforce.
• **Customers (Future):** Advancement of SAB-142 into Phase 2b trials moves the company closer to potentially bringing a new treatment for Type 1 Diabetes to market, addressing an unmet medical need.
• **Creditors:** The substantial capital raise improves the company's liquidity and financial stability, reducing immediate credit risk.

Next Steps

• Advance SAB-142 into a Phase 2b clinical trial called the SAFEGUARD study, with an expected start date in December 2025.
• Utilize the data from the Phase 2b SAFEGUARD study as supportive evidence for future regulatory approval of SAB-142.
• Hold a special meeting of stockholders to approve the issuance of common stock upon conversion of the Series B Preferred Stock.
• File a resale registration statement on Form S-3 (or S-1) for the Registrable Securities from the Series B Offering promptly after filing the definitive proxy statement for stockholder approval.
• Potentially seek additional funding through equity or debt financings, or other third-party arrangements in the future.
• Expand workforce and invest in the advancement of the lead therapeutic candidate in preparation for potential commercialization.

Key Dates

Recommendation

The company's financial performance for the quarter was poor, with increased losses and no revenue. However, the subsequent $175 million capital raise is a critical positive development, providing necessary funding for the Phase 2b SAFEGUARD study of SAB-142, which is essential for the company's future. This funding addresses immediate liquidity concerns and signals investor confidence in the lead candidate. The significant potential dilution from the Series B offering (2,690% of current outstanding common stock) is a major concern for existing shareholders, creating substantial overhang. Given the high-risk, high-reward nature of clinical-stage biopharma and the trade-off between critical funding and dilution, a 'hold' recommendation is appropriate. Investors should monitor the progress of the SAFEGUARD study and the impact of the dilution.

Keywords

Biopharmaceutical, Type 1 Diabetes, T1D, Immunotherapeutics, Polyclonal Antibodies, SAB-142, Clinical Stage, FDA IND, Phase 2b SAFEGUARD, SEC Filing, 10-Q, Capital Raise, Private Placement, Biotech, Autoimmune Disorders